Quarterly report pursuant to Section 13 or 15(d)

Reverse Merger - Summary of Pro Forma Results of Operation (Detail)

v3.8.0.1
Reverse Merger - Summary of Pro Forma Results of Operation (Detail) - OncoGenex Pharmaceuticals, Inc [Member] - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Business Acquisition [Line Items]        
Revenue       $ 5,062
Net loss applicable to common shareholders $ (9,730) $ (4,197) $ (10,100) $ (15,034)
Net loss per share-basic and diluted $ (1.35) $ (0.14) $ (4.15) $ (0.50)
Weighted average shares 7,225,826 30,013,928 2,435,095 29,925,479